In Vitro Combination of Terbinafine with Ketoconazole Against Aspergillus Species with Terbinafine High MIC Values Isolated From Otomycosis.
Aspergillus species
Combination
Ketoconazole
Otomycosis
Terbinafine
Journal
Mycopathologia
ISSN: 1573-0832
Titre abrégé: Mycopathologia
Pays: Netherlands
ID NLM: 7505689
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
07
09
2022
accepted:
20
11
2022
medline:
11
5
2023
pubmed:
1
12
2022
entrez:
30
11
2022
Statut:
ppublish
Résumé
Otomycosis is a common mycotic infection of the external auditory canal, and Aspergillus species are one of the most frequent causative agents worldwide. The limited antifungal arsenal, the high toxicity and side effects of antifungal agents, and the growing resistance to the currently available antifungals underscore the need for new therapeutic strategies. The present study aimed to evaluate the combined in vitro efficacy of terbinafine and ketoconazole against Aspergillus species with terbinafine high MIC values isolated from patients with otomycosis.84 Aspergillus species with high MIC values to terbinafine (≥ 4 µg/ml), consisting of A. flavus, A. tubingensis, A. niger, and A. terreus, were included in this study. The checkerboard microdilution method evaluated the in vitro interactions using the CLSI reference technique. Synergistic effects were observed for 66.67% (56/84) of all isolates (FICI ranging from 0.19 to 0.5). However, the interactions of terbinafine and ketoconazole exhibited indifference in 33.33% (28/84) of the isolates, and no antagonism was observed for any combination. The interaction of terbinafine and ketoconazole showed synergistic activity against Aspergillus species with high MIC values, suggesting that this is an alternative and promising approach for treating otomycosis.
Identifiants
pubmed: 36449121
doi: 10.1007/s11046-022-00698-7
pii: 10.1007/s11046-022-00698-7
doi:
Substances chimiques
Terbinafine
G7RIW8S0XP
Ketoconazole
R9400W927I
Antifungal Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
119-127Subventions
Organisme : Invasive Fungi Research Center, Mazandaran University of Medical Sciences
ID : 8937
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Sangaré I, Amona FM, Ouedraogo RW-L, Zida A, Ouedraogo MS. Otomycosis in Africa: epidemiology, diagnosis and treatment. J Med Mycol. 2021;31(2):101115.
doi: 10.1016/j.mycmed.2021.101115
Nipa K, Kamal A, Imtiaj A. Prevalence and clinicomycological studies of Otomycosis: a review. J Bio-Science. 2020;28:121–35.
doi: 10.3329/jbs.v28i0.44718
Jing R, Yang W-H, Xiao M, Li Y, Zou G-L, Wang C-Y, et al. Species identification and antifungal susceptibility testing of Aspergillus strains isolated from patients with otomycosis in northern China. J Microbiol Immunol Infect. 2022;55(2):282–90.
doi: 10.1016/j.jmii.2021.03.011
pubmed: 33839057
Anwar K, Gohar MS. Otomycosis; clinical features, predisposing factors and treatment implications. Pak J Med Sci. 2014;30(3):564.
pubmed: 24948980
pmcid: 4048507
Kiakojuri K, Mahdavi Omran S, Roodgari S, Taghizadeh Armaki M, Hedayati MT, Shokohi T, et al. Molecular identification and antifungal susceptibility of yeasts and molds isolated from patients with otomycosis. Mycopathologia. 2021;186(2):245–57.
doi: 10.1007/s11046-021-00537-1
pubmed: 33718990
Khan MA, Akram S, Anwar K, Ahmad A, Khan M, Hakim A. Prevalence, clinical profile and seasonal variation of otomycosis in Pakistan. Int J Pathol. 2020;26–30.
Hagiwara S, Tamura T, Satoh K, Kamewada H, Nakano M, Shinden S, et al. The molecular identification and antifungal susceptibilities of Aspergillus species causing otomycosis in Tochigi. Japan Mycopathologia. 2019;184(1):13–21.
doi: 10.1007/s11046-018-0299-9
pubmed: 30291485
Wu S, Cheng Y, Lin S, Liu H. A Comparison of antifungal drugs and traditional antiseptic medication for otomycosis treatment: a systematic review and meta-analysis. Frontiers Surg. 2021;8.
Gharaghani M, Halvaeezadeh M, Jalaee GA, Taghipour S, Kiasat N, Mahmoudabadi AZ. Antifungal susceptibility profiles of otomycosis etiological agents in Ahvaz. Iran Current medical mycology. 2020;6(2):18.
pubmed: 33628977
Gu X, Cheng X, Zhang J, She W. Identification of the fungal community in otomycosis by internal transcribed spacer sequencing. Frontiers Microbiol. 2022;13.
Zhang L, Wang X, Houbraken J, Mei H, Liao W, Hasimu H, et al. Molecular identification and in vitro antifungal susceptibility of aspergillus isolates recovered from otomycosis patients in Western China. Mycopathologia. 2020;185(3):527–35.
doi: 10.1007/s11046-020-00448-7
pubmed: 32346838
Kazemi A, Majidinia M, Jaafari A, Mousavi SAA, Mahmoudabadi AZ, Alikhah H. Etiologic agents of otomycosis in the North-Western area of Iran. Jundishapur J Microbiol. 2015;8(9).
Jimenez-Garcia L, Celis-Aguilar E, Díaz-Pavón G, Muñoz Estrada V, Castro-Urquizo Á, Hernández-Castillo N, et al. Efficacy of topical clotrimazole vs. topical tolnaftate in the treatment of otomycosis. a randomized controlled clinical trial. Brazilian J Otorhinolaryngology. 2020;86:300–7.
doi: 10.1016/j.bjorl.2018.12.007
Morishita N, Oshima A, Ninomiya J, Hamaguchi T, Takiuchi I. Dermatophytosis of the external auditory meatus. Nippon Ishinkin Gakkai Zasshi. 2000;41(3):197–9.
doi: 10.3314/jjmm.41.197
Latha R, Sasikala R, Muruganandam N. Chronic otomycosis due to malassezia spp. J Glob Infect Dis. 2010;2(2):189.
doi: 10.4103/0974-777X.62875
pubmed: 20606976
pmcid: 2889660
Trabelsi H, Neji S, Hadrich I, Sellami M, Khemakhem N, Sellami H, et al. Unusual case of otomycosis caused by Saksenaea vasiformis. Med Mycol Case Rep. 2020;27:68–71.
doi: 10.1016/j.mmcr.2020.02.001
pubmed: 32082981
pmcid: 7019119
Prasad SC, Kotigadde S, Shekhar M, Thada ND, Prabhu P, D’Souza T et al. Primary otomycosis in the Indian subcontinent: predisposing factors, microbiology, and classification. Int J Microbiol. 2014;2014.
Kryukov A, Kunel’skaya N, Kunel’skaya VY, Ivoilov AY, Turovskiy A, Shadrin G, et al. Otomycosis: the modern view of etiology and management. Vestn Otorinolaringol. 2018;83(1):48–51.
doi: 10.17116/otorino201883148-51
pubmed: 29488497
Mofatteh MR, Yazdi ZN, Yousefi M, Namaei MH. Comparison of the recovery rate of otomycosis using betadine and clotrimazole topical treatment. Braz J Otorhinolaryngol. 2018;84:404–9.
doi: 10.1016/j.bjorl.2017.04.004
pubmed: 28549873
Marcy M, Takata G, Shekelle LC, Mason W, Wachsman L, Ernst R, et al. Management of acute otitis media. database of abstracts of reviews of effects (DARE): Quality-assessed Reviews [Internet]. Centre for Reviews and Dissemination (UK); 2001.
Nemati S, Hassanzadeh R, Khajeh Jahromi S, Delkhosh Nasrollah Abadi A. Otomycosis in the north of Iran: common pathogens and resistance to antifungal agents. Eur Archives Oto-Rhino-Laryngology. 2014;271(5):953–7.
doi: 10.1007/s00405-013-2486-0
Shokoohi G, Sefidmazgi RR, Etehadnezhad M, Ahmadi B, Javidnia J, Nouripour-Sisakht S, et al. In vitro antifungal activity of luliconazole, efinaconazole, and nine comparators against Aspergillus and Candida strains isolated from otomycosis. Jundishapur J Microbiol. 2021;14(4).
Scorzoni L, de Paula e Silva AC, Marcos CM, Assato PA, de Melo WC, de Oliveira HC, et al. Antifungal therapy: new advances in the understanding and treatment of mycosis. Frontiers Microbiol. 2017;8:36.
Vassilopoulos S, Mylonakis E. Avenues for antifungal drug discovery and development: Where to now?: Taylor & Francis; 2022.
CLSI. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi reCsMCaLSIW, PA.
Ernst EJ, Rogers PD. Antifungal agents: methods and protocols. Springer Science & Business Media; 2005.
Fisher MC, Alastruey-Izquierdo A, Berman J, Bicanic T, Bignell EM, Bowyer P, et al. Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol. 2022;1–15.
Karaarslan A, Arikan S, Ozcan M, Ozcan K. In vitro activity of terbinafine and itraconazole against Aspergillus species isolated from otomycosis. Mycoses. 2004;47(7):284–7.
doi: 10.1111/j.1439-0507.2004.00988.x
pubmed: 15310330
Szigeti G, Kocsubé S, Dóczi I, Bereczki L, Vágvölgyi C, Varga J. Molecular identification and antifungal susceptibilities of black Aspergillus isolates from otomycosis cases in Hungary. Mycopathologia. 2012;174(2):143–7.
doi: 10.1007/s11046-012-9529-8
pubmed: 22359155
Haghani I, Shams-Ghahfarokhi M, Dalimi Asl A, Shokohi T, Hedayati MT. Molecular identification and antifungal susceptibility of clinical fungal isolates from onychomycosis (uncommon and emerging species). Mycoses. 2019;62(2):128–43.
doi: 10.1111/myc.12854
pubmed: 30255665
Abastabar M, Haghani I, Shokohi T, Hedayati MT, Aghili SR, Jedi A, et al. Low in vitro antifungal activity of tavaborole against yeasts and molds from onychomycosis. Antimicrob Agents Chemother. 2018;62(12):e01632-e1718.
doi: 10.1128/AAC.01632-18
pubmed: 30224524
pmcid: 6256807
Abastabar M, Zaedi A, Shabanzadeh S, Nosratabadi M, Moazeni M, Aghili SR, et al. In vitro activity of 23 antifungal drugs against 54 clinical and environmental Aspergillus oryzae isolates. Mycoses. 2022.
Xie L, Zhai H, Zhao J, Sun S, Shi W, Dong X. Antifungal susceptibility for common pathogens of fungal keratitis in Shandong Province. China Am J Ophthalmol. 2008;146(2):260-5e1.
doi: 10.1016/j.ajo.2008.04.019
pubmed: 18547535
Kantarcioglu A, Yucel A. In-vitro activities of terbinafine, itraconazole and amphotericin B against Aspergillus and Cladosporium species. J Chemother. 2002;14(6):562–7.
doi: 10.1179/joc.2002.14.6.562
pubmed: 12583546
Moore CB, Walls CM, Denning DW. In vitro activities of terbinafine against Aspergillus species in comparison with those of itraconazole and amphotericin B. Antimicrob Agents Chemother. 2001;45(6):1882–5.
doi: 10.1128/AAC.45.6.1882-1885.2001
pubmed: 11353643
pmcid: 90563
Aktas E, Yigit N. Determination of antifungal susceptibility of Aspergillus spp responsible for otomycosis by E-test method. J de mycologie médicale. 2009;19(2):122–5.
doi: 10.1016/j.mycmed.2009.03.004
Szigeti G, Sedaghati E, Mahmoudabadi AZ, Naseri A, Kocsube S, Vágvölgyi C, et al. Species assignment and antifungal susceptibilities of black aspergilli recovered from otomycosis cases in Iran. Mycoses. 2012;55(4):333–8.
doi: 10.1111/j.1439-0507.2011.02103.x
pubmed: 21895787
Ryder N, Leitner I. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med Mycol. 2001;39(1):91–5.
doi: 10.1080/mmy.39.1.91.95
pubmed: 11270414
Mosquera J, Sharp A, Moore C, Warn P, Denning D. In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. J Antimicrob Chemother. 2002;50(2):189–94.
doi: 10.1093/jac/dkf111
pubmed: 12161398
Biancalana FSC, Lyra L, Schreiber AZ. In vitro evaluation of the type of interaction obtained by the combination of terbinafine and itraconazole, voriconazole, or amphotericin B against dematiaceous molds. Antimicrob Agents Chemother. 2011;55(9):4485–7.
doi: 10.1128/AAC.01015-10
pubmed: 21690288
pmcid: 3165310
Campitelli M, Zeineddine N, Samaha G, Maslak S. Combination antifungal therapy: a review of current data. J Clin Med Res. 2017;9(6):451.
doi: 10.14740/jocmr2992w
pubmed: 28496543
pmcid: 5412516
Belanger ES, Yang E, Forrest GN. Combination antifungal therapy: when, where, and why. Curr Clin Microbiol Rep. 2015;2(2):67–75.
doi: 10.1007/s40588-015-0017-z